TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by the Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic to identify patients with ROS1- positive non-small cell lung cancer (NSCLC) for Rozlytrek®, a selective tyrosine kinase inhibitor which comes in 100 mg or 200 mg capsules (common name: entrectinib) marketed by Chugai Pharmaceutical Co., Ltd.
Read the full press release below:
JointRelease_ROS1_Entrectinib_Aug09-2022_final
.pdf
Download PDF • 440KB